An observational study in HIV Infections, sponsored by University of Zurich. Recruiting at 1 site in Switzerland. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-05-08.
Sponsored by University of Zurich · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 81 studies in HIV Infections with a site in Switzerland — 4 open to participants now, 6 under way, 3 of them phase 3. HIV Infections · Switzerland.
Among the 81 studies in HIV Infections with a site in Switzerland, this one is the 6th largest by planned enrollment of the 17 observational ones that give a count, is the only one that started in 2022, is one of 17 observational ones, and was the 78th registered.
4,737 studies on the registry are indexed under HIV Infections; 247 are open to participants now.
Browse HIV Infections studies →4 of the 81 studies in HIV Infections with a site in Switzerland are open now. Recruiting first, the newest first:
Gilead Sciences · Sites in Switzerland, United States, Australia and 5 more countries
Ages 18+
University of Zurich · Sites in Switzerland
Ages 18+
Centre Hospitalier Universitaire Vaudois · Sites in Switzerland
Ages 18+
A study can be open while its sites in Switzerland have not opened yet or have stopped. Only those recruiting at a site in Switzerland →
Of the 159 HIV Infections studies recruiting now, 104 (65%) set no upper age limit and 42 (26%) stop at 75 or younger; 31 take children under 18; 60 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
81 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 14 · Phase 3 32 · Phase 4 10
First in 1999; this study’s year is marked. 1 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 600 is above the median of 200 across 781 observational studies indexed under HIV Infections.
Median enrollment 438 across the 61 interventional studies, 249 across the 17 observational. Of the 68 that completed or were terminated, 28 (41%) have results posted.
This tab as a report to print or save as PDF → With an account.
41 of 81 have an industry lead sponsor. The 10 most frequent:
University of Zurich is the lead sponsor of 1,051 studies on the registry; 134 are open to participants now.
University of Zurich has 5 studies filed under HIV Infections — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 81 studies in HIV Infections with a site in Switzerland, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study aims to characterize Swiss HIV Cohort Study participants initiating the CAB+RPV LA regimen, assess adherence to Swiss label indications, and describe treatment outcomes in this large, multicentre, heterogeneous, high-income setting. Moreover, the study aims to assess virological, immunological, demographic, clinical, and behavioural factors associated with viral failure under CAB+RPV LA regimen.
The study population consists of SHCS participants initiating the CAB+RPV LA regimen and a matched control population on a SOC oral regimen (including dual drug regimens)
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Swiss HIV Cohort Study participants initiating the CAB+RPV LA regimen
Drug: VOCABRIA 30Mg Tablet · Drug: EDURANT 25Mg Tablet · Drug: Cabotegravir Injectable Suspension · Drug: Rilpivirine Injectable Suspension · Biological: Intact proviral DNA assay · Biological: Full-length sequencing
Matched control population on a standard of care oral regimen
Biological: Intact proviral DNA assay · Biological: Full-length sequencing
CAB 30 mg Film-coated tablets
Also known as: Cabotegravir Tablets
RPV 25 mg film-coated tablets
Also known as: Rilpivirine Tablets
CAB LA 600 mg prolonged release suspension for injection (3 mL)
Also known as: Vocabria
RPV LA 900 mg prolonged release suspension for injection (3 mL)
Also known as: Rekambys
HIV-1 latent reservoir size
Proviral DNA
Proportion of individuals with viral blips
Proportion of individuals with viral blips (defined as one HIV-1 RNA \>50 and \<400 c/mL with a next HIV-1 RNA \<50 copies/ml)
Time frame: Month 24
Proportion of individuals with confirmed viral failures
Proportion of individuals with confirmed viral failures (defined as two consecutive HIV-1 RNA ≥ 50 c/mL)
Time frame: Month 24
Proportion of individuals switching off CAB+RPV LA to previous or another oral regimen
Proportion of individuals switching off CAB+RPV LA to previous or another oral regimen after HIV-1 RNA levels of \>50 to \<400 copies/mL and \>400 copies/mL
Time frame: Month 24
Time to viral failure
Overall time to confirmed viral failures (defined as two consecutive HIV-1 RNA ≥ 50 c/mL)
Time frame: Up to month 24
Proportion of participants who discontinue treatment due to drug-related reasons
Proportion of participants who discontinue treatment due drug-related reasons and re-suppression regimens (such as adverse events, confirmed viral failure, low level viremia or low blood concentration measurements) including the choice of re-suppression regimens.
Time frame: Month 24
Proportion of participants who discontinue treatment due to drug-unrelated reasons
Proportion of participants who discontinue treatment due drug-unrelated reasons and re-suppression regimens (such as patient wish, death, migration, and loss to follow-up) including the choice of re-suppression regimens.
Time frame: Month 24
Proportion of participants by characteristics
- Proportion of participants by socio-demographic and clinical characteristic(s) (e.g., by age, sex, body mass index, race, geographic origin, education, transmission mode, HIV-1 RNA levels, CD4 cell count, duration of HIV-1 infection, HIV-1 subtype, previous regimen, genotypic resistance profile, coinfections, lifestyle variables, and co-medications)
Time frame: Month 24
Overall adherence to Swiss label indication in CAB+RPV LA prescriptions
- Overall adherence to Swiss label indication in CAB+RPV LA prescriptions between care providers, such as university hospital versus private physicians, and among nationwide centres
Time frame: Month 24
Overall adherence to the proposed injection schedules
- Overall adherence to the proposed injection schedules quantified by deriving an CAB+RPV LA adherence threshold (e.g., accounting for any missed injection, daily oral bridging ART, and delayed injection of +7 days according to the Swiss label indication)
Time frame: Month 24
Proportion of participants by treatment adherence category
- Proportion of participants by treatment adherence categories (e.g., optimal, sub-optimal, and poor adherence)
Time frame: Month 24
Investigate in-depth factors associated with viral blips and viral failure
Proportion of individuals by risk factor(s) (e.g., by body mass index, race, geographic origin, education, HIV-1 RNA levels, CD4 cell count, duration of HIV-1 infection, HIV-1 subtype, previous regimen, treatment adherence, CAB+RPV LA plasma concentrations measured at time of failure, genotypic resistance profile , lifestyle variables, and co-medications)
Time frame: Month 24
Measure intact proviral DNA as potential predictor for viral failure
Measure intact proviral DNA as potential predictor for viral failure among PWH initiating CAB+RPV LA regimen and compare with the matched control population on a SOC oral regimen
Time frame: Month 24
Assessment of resistance associated mutations from proviral DNA as potential predictor for viral failure
Assessment of resistance associated mutations from proviral DNA as potential predictor for viral failure among PWH initiating CAB+RPV LA regimen and compare with the matched control population on a SOC oral regimen
Time frame: Month 24
Plan to share: Undecided
No publications or documents are linked to this record.
Started Mar 2022 (actual). Primary completion is estimated for Dec 2025, 45 months after the start.
Of 187 non-industry observational studies under HIV Infections, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 69. This study's planned 45 months is above that.
Counting every sponsor, half of 201 studies reached it within 38 months; a quarter within 16 and three quarters within 69.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.